6YI8

HUMAN FGFR4 KINASE DOMAIN (447-753) IN COMPLEX WITH ROBLITINIB

Summary for 6YI8

• Entry DOI: 10.2210/pdb6yi8/pdb
• Descriptor: Fibroblast growth factor receptor 4, N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-methanoyl-6-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, SULFATE ION, ... (4 entities in total)
• Functional Keywords: tyrosine kinase inhibitor, covalent reversible inhibitor, fgfr4, roblitinib, transferase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 70178.74

Authors

Ostermann, N. (deposition date: 2020-04-01, release date: 2020-09-30, Last modification date: 2024-10-09)

Primary citation

Fairhurst, R.A.,Knoepfel, T.,Buschmann, N.,Leblanc, C.,Mah, R.,Todorov, M.,Nimsgern, P.,Ripoche, S.,Niklaus, M.,Warin, N.,Luu, V.H.,Madoerin, M.,Wirth, J.,Graus-Porta, D.,Weiss, A.,Kiffe, M.,Wartmann, M.,Kinyamu-Akunda, J.,Sterker, D.,Stamm, C.,Adler, F.,Buhles, A.,Schadt, H.,Couttet, P.,Blank, J.,Galuba, I.,Trappe, J.,Voshol, J.,Ostermann, N.,Zou, C.,Berghausen, J.,Del Rio Espinola, A.,Jahnke, W.,Furet, P.
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
J.Med.Chem., 63:12542-12573, 2020

PubMed Abstract: FGF19 signaling through the FGFR4/β-klotho receptor complex has been shown to be a key driver of growth and survival in a subset of hepatocellular carcinomas, making selective FGFR4 inhibition an attractive treatment opportunity. A kinome-wide sequence alignment highlighted a poorly conserved cysteine residue within the FGFR4 ATP-binding site at position 552, two positions beyond the gate-keeper residue. Several strategies for targeting this cysteine to identify FGFR4 selective inhibitor starting points are summarized which made use of both rational and unbiased screening approaches. The optimization of a 2-formylquinoline amide hit series is described in which the aldehyde makes a hemithioacetal reversible-covalent interaction with cysteine 552. Key challenges addressed during the optimization are improving the FGFR4 potency, metabolic stability, and solubility leading ultimately to the highly selective first-in-class clinical candidate roblitinib.

PubMed: 32930584
DOI: 10.1021/acs.jmedchem.0c01019

Experimental method

X-RAY DIFFRACTION (2.13 Å)